Human immunodeficiency virus type 1 (HIV-1)-infected individuals often exhibit multiple hematopoietic abnormalities reaching far beyond loss of CD4+ lymphocytes. We used the SCID-hu (Thy/Liv) mouse (severe combined immunodeficient mouse transplanted with human fetal thymus and liver tissues), which provides an in vivo system whereby human pluripotent hematopoietic progenitor cells can be maintained and undergo T-lymphoid differentiation and wherein HIV-1 infection causes severe depletion of CD4-bearing human thymocytes. Herein we show that HIV-1 infection rapidly and severely decreases the ex vivo recovery of human progenitor cells capable of differentiation into both erythroid and myeloid lineages. However, the total CD34+ cell population is not depleted. Combination antiretroviral therapy administered well after loss of multilineage progenitor activity reverses this inhibitory effect, establishing a causal role of viral replication. Taken together, our results suggest that pluripotent stem cells are not killed by HIV-1; rather, a later stage important in both myeloid and erythroid differentiation is affected. In addition, a primary virus isolated from a patient exhibiting multiple hematopoietic abnormalities preferentially depleted myeloid and erythroid colony-forming activity rather than CD4-bearing thymocytes in this system. Thus, HIV-1 infection perturbs multiple hematopoietic lineages in vivo, which may explain the many hematopoietic defects found in infected patients.
the observed depletion of CD4\(^+\) thymocytes. Furthermore, this model has been used to determine the viral accessory genes involved in pathogenesis (3, 16) and the response of HIV-1 to antiviral therapies (19, 25, 26, 33). Previously, McCune et al. (24) reported that human pluripotent hematopoietic progenitor cells capable of giving rise to myeloid and erythroid colonies ex vivo in response to cytokines are maintained for extended periods of time in this model.

The SCID-hu system has thus proven relevant to the clinical situation, is amenable to manipulation and analyses, and offers an opportunity to investigate the effects of HIV-1 infection on multiple arms of hematopoiesis. Here we report that HIV-1 infection profoundly decreases the ability to recover hematopoietic colony-forming activity (CFA) from Thy/Liv implants. However, this effect is reversible following administration of combination antiretroviral therapy. Our studies thus establish a causal effect of viral replication on hematopoiesis of multiple lineages. In addition, the reversible nature of this inhibitory effect following therapy suggests that neither the very immature hematopoietic progenitor cell nor the differentiation-inducing microenvironment is destroyed by high levels of HIV-1. Furthermore, we identify a viral strain, isolated from a pediatric patient exhibiting severe hematologic abnormalities, which preferentially inhibits hematopoietic CFA rather than inducing CD4\(^+\) thymocyte depletion. Together our studies suggest that HIV-1 may be directly responsible for many of the hematopoietic perturbations seen in infected individuals.

FIG. 1. (A) HIV-1-induced inhibition of hematopoietic colony formation. Each bar represents data obtained from four uninfected or four HIV-1-infected animals. Sequential biopsies from the same implants were performed at both 3 and 6 weeks postinfection. Standard deviations were calculated by taking into account the duplicate sets of plates for each sample. The data from a second experiment (not shown) were similar to those shown. (B) Inhibition of hematopoiesis is an in vivo phenomenon. Cells from uninfected and HIV-1NL4-3-infected Thy/Liv implants (four animals each) obtained at 3 and 5 weeks postinfection were washed, mixed in equal numbers, and plated on methylcellulose. Hematopoietic colonies were evaluated as described in Materials and Methods. (C) PCR analyses of 23 representative myeloid and erythroid colonies, 7 derived from mock-infected and 16 derived from virus (8 of NL4-3 and 8 of JR-CSF strain)-infected Thy/Liv implants. These include six infected colonies. The lanes showing myeloid and erythroid colonies are indicated as W (white) and R (red), respectively. WR is a putative mixed progenitor colony. The letter A preceding W/R/WR indicates that the methylcellulose supporting the colony growth contained AZT (1 \(\mu\)g/ml). Quantitation for proviral DNA copies was done with a primer pair for \(\beta\)-globin as internal standard.
TABLE 1. HIV-1-induced inhibition of hematopoiesis at 3 and 6 weeks postinfection

<table>
<thead>
<tr>
<th>Virus infection (no. of animals)</th>
<th>HIV-1 phenotype</th>
<th>3 wk postinfection</th>
<th>6 wk postinfection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV-1 copies/100,000 cells</td>
<td>% Total CD4</td>
<td>Myeloid colonies</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mock (5)</td>
<td>0</td>
<td>96 ± 1</td>
<td>124 ± 10</td>
</tr>
<tr>
<td>V3 (4)</td>
<td>NSI</td>
<td>6.9 × 10^2 ± 8.0 × 10^2</td>
<td>96 ± 1</td>
</tr>
<tr>
<td>V20 (4)</td>
<td>NSI</td>
<td>7.6 × 10^2 ± 4.1 × 10^2</td>
<td>25 ± 6</td>
</tr>
<tr>
<td>V19 (5)</td>
<td>NSI</td>
<td>1.7 × 10^2 ± 2.4 × 10^2</td>
<td>92 ± 1</td>
</tr>
<tr>
<td>V22 (5)</td>
<td>SI</td>
<td>&lt;0.5 × 10^2 ± 1.3 × 10^2</td>
<td>96 ± 1</td>
</tr>
<tr>
<td>V1 (4)</td>
<td>SI</td>
<td>4.0 × 10^2 ± 1.3 × 10^2</td>
<td>96 ± 1</td>
</tr>
<tr>
<td>V10460 (5)</td>
<td>SI</td>
<td>2.2 × 10^2 ± 1.5 × 10^2</td>
<td>11 ± 6</td>
</tr>
<tr>
<td>V34 (4)</td>
<td>SI</td>
<td>1.6 × 10^2 ± 0.8 × 10^2</td>
<td>47 ± 27</td>
</tr>
<tr>
<td>NL4-3 (6)</td>
<td>SI</td>
<td>3.3 × 10^2 ± 2.0 × 10^2</td>
<td>85 ± 7</td>
</tr>
</tbody>
</table>

* Pathogenicity of several primary HIV-1 isolates following infection of Thy/Liv tissue. The phenotype of each isolate as determined by MTC2 cell tropism is indicated. HIV-1 NL4-3 is used as a comparative control. Cells (the majority of which are thymocytes) from infected and control implants were obtained at 3 and 6 weeks postinfection. The primary virus isolates are compared for their effects on myeloid and erythroid CFA. CD4+ thymocyte depletion (percent total CD4), and virus replicative ability in thymocytes by quantitative PCR. Percent total CD4 includes both CD4+ CD8+ and CD4+ CD8− subsets.

MATERIALS AND METHODS

Construction and infection of SCID-hu mice. SCID mice were transplanted with a mixture of human fetal thymus and liver tissue as previously described and infected with 100 infectious units (IU) of HIV-1 by direct intraimplant injection (2, 28). At specific time intervals postinfection, sequential wedge biopsies (~25% of each implant) were obtained, with mock-infected SCID-hu mice serving as negative controls.

Drug treatment of animals. The combination drug treatment used was identical to that previously described (33) and included the following: protease inhibitor A77003 (Abbott Laboratories, Chicago, Ill.) at a dose of 50 mg/kg of body weight/day, delivered intraperitoneally, and ddf (Aldrich Chemical Co., Milwaukee, Wis.) at a dose of 50 mg/kg/day, also given intraperitoneally. Zidovudine (AZT; Aldrich) was delivered in drinking water (0.4 mg/ml) at a dose of 66 mg/kg/day, based on an estimate of consumption of 3 ml of water/day/animal and an average weight of 20 g/mouse.

Primary HIV-1 strains. (i) Virus isolates from hematopoietic patients. Viruses were isolated from sequentially acquired cryopreserved peripheral blood mononuclear cells (PBMCs) obtained from two HIV-1-infected hematopoietics who were monitored over approximately 4 years. Both subjects experienced a precipitous decline in CD4+ cells associated with a switch from non-syncytium-inducing (NSI) to syncytium-inducing (SI) strains. Viruses V26, V34, V19, and V22 were derived from one of these patients, and V1, V3, and V10460 were derived from the other.

(ii) Virus isolates from patients with hematopoietic abnormalities. The isolates PT3MO and PTSMO were derived by coculture PBMCs from an infant patient at 3 and 8 months of age, respectively. The infant was a 1.6-kg 35-week-old premature male born to a 39-year-old gravidity VI, para VII mother who was unaware of her HIV-1-seropositive status. The infant had an unremarkable stay in the nursery intensive care unit and did not require intubation or blood product transfusion. After discharge by 6 weeks of age, she developed upper lobe pneumonitis and severe anemia and neutropenia with an absolute neutrophil count of 75/mm³. She had repeated episodes of respiratory distress, pneumonia, otitis media, and hepatosplenomegaly and severe pancytopenia. She had several documented leukocyte counts with no neutrophils or smear and 95% lymphocytes with a hemocrit of 18. HIV-1 infection was diagnosed by a positive virus culture and DNA PCR. She had a low CD4 cell count of 810 cells/mm³ at 3 months of age, which fell to 414/mm³ by 4 months and to below 100/mm³ by 8 months. At 4 months of age, she was started on a treatment protocol of AZT and nevirapine and given prophylactic sulfamethoxazole-trimethoprim (Bactrim). She progressed rapidly to AIDS with associated neurological developmental delay and with cytomegalovirus retinitis which was treated with ganciclovir. She continued to have problems with anemia and neutropenia. She developed cardiomyopathy and expired at 10 months of age due to complications of AIDS. Her mother and older sibling of 2 years of age were also diagnosed with HIV-1 infection.

Hematopoietic CFA in Thy/Liv implants. Total Thy/Liv cells (10⁵) were suspended in 2 ml of methylcellulose medium (Methocult H4320; Stem Cell Technologies Inc., Vancouver, British Columbia, Canada) containing 100U/ml each of stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3, and IL-6 per ml and 2 U of erythropoietin per ml to allow the differentiation of progenitor cells. The cells were then seeded in duplicate 1-ml cultures, and hematopoietic colonies were enumerated by microscopy.

Quantitative PCR to detect HIV DNA. To quantitate proviral burden in Thy/Liv implants, PCR was performed with end-labeled primers specific for the R/U5 region of the viral long terminal repeat and for human β-globin as an internal standard. Quantitation (number of copies of HIV/100,000 cells) was achieved by comparison to standard curves consisting of cloned viral DNA and uninfected PBMC DNA, followed by radiolabeled image analysis as previously described (17, 33, 34).

To assess the presence of provirus in hematopoietic colonies, we collected single colonies of 500 cells or larger 2 weeks after plating, while viewing under a microscope. The cells were washed and lysed, and the DNA was subjected to phenol-chloroform extraction in the presence of RNA (10 mg/ml) as a carrier, followed by ethanol precipitation. The resultant DNA was subjected to quantitative PCR analysis (25 cycles) for HIV-1 and human β-globin gene sequences, which confirmed the presence of human cellular DNA.

Flow cytometry. Cells (0.5 × 10⁶) from mock- or HIV-infected implants were stained with a three-color mixture of monoclonal antibodies consisting of mouse anti-human CD4-phycoerythrin (CD4-PE), CD8-fluorescein isothiocyanate (CD8-FITC), and CD3-peridinin chlorophyll protein (CD3-PerCP), obtained from Becton Dickinson, Mountain View, Calif. The cells were fixed in phosphate-buffered saline containing 1% formalin, and data were acquired on a Becton Dickinson FACScan flow cytometer. Isotype controls were used to set compensation for the analysis. The data were converted by a FACS Convert program for analysis, using CellQuest software to calculate the percentage of cells stained by each label. Other conjugated monoclonal antibodies purchased from Becton Dickinson and used similarly include anti-human CD34-FTIC and CD45-PerCP and isotype control antibodies, −PE, −FITC, and −PerCP. Other isotype control antibodies, goat anti-mouse (GAM) IgG2a (immunoglobulin G2a)-PE, IgG2b-PE, and IgG2b-FITC, were purchased from Caltag Laboratories (South San Francisco, Calif.). The anti-CXCR4 monoclonal antibody 12G5 (12) was from the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (donated by J. Hoxie).

RESULTS AND DISCUSSION

Effects of HIV-1 infection on hematopoietic CFA. To investigate the effects of HIV-1 infection on early events in myeloid and erythroid hematopoiesis, Thy/Liv cells were plated in methylcellulose in the presence of IL-3, IL-6, SCF, GM-CSF, and erythropoietin. Consequently, and also as previously reported (24), hematopoietic progenitor cells able to differentiate into myeloid and erythroid colonies in vitro were reproducibly obtained from cells from uninfected Thy/Liv implants. The fetal liver origin of these precursors was confirmed in that essentially no colonies were detectable from the same number of fetal thymocytes similarly cultured. Little variation in recov-
ery of these precursor cells is seen following multiple simultaneous or sequential biopsies of the same implant or from multiple Thy/Liv implants generated from the same fetal tissue donor (Fig. 1A and B). Since recovery of cells from implants derived from different fetal tissue donors varied, each individual experiment herein was conducted with implants derived from the same fetal donor.

Following infection of Thy/Liv implants with each of two well-defined molecular clones of HIV-1, both myeloid and erythroid CFA were decreased (Fig. 1A). The colony numbers were reduced to minimal levels (~10%) by 3 weeks postinfection (Fig. 1A and Table 1) with the CXCR4-tropic SI HIV-1NL4-3 strain (1). The NSI CCR5-tropic strain, HIV-1JR-CSF (22), also inhibited CFA, but less aggressively than did the SI strain. Inclusion of AZT (1 μg/ml) in the methylcellulose did not increase the numbers of colonies formed, suggesting that virus infection in vitro was not causing this effect (not shown).

To confirm that the observed hematopoietic inhibition occurred in vivo rather than in vitro due to the presence of infected thymocytes, equal numbers of cells from uninfected and infected implants were mixed ex vivo prior to culture in methylcellulose (Fig. 1B). The presence of infected thymocytes did not affect the CFA of cells from uninfected implants; thus, infection or exposure to the products of infected cells in vitro was not responsible for the observed inhibition.

To determine if direct infection of hematopoietic progenitor cells was occurring, resulting in loss of CFA, we performed quantitative PCR amplification using primers specific for viral sequences (34). These studies detected proviral DNA associated with only 10 of 100 myeloid and erythroid colonies derived from infected implants (Fig. 1C). Furthermore, proviral DNA was at a low copy number compared to quantitated human β-globin gene sequences (~0.05 copy/cell), indicating that provirus was not present in the original precursor cells forming these colonies. This low level of viral DNA is most likely contamination from infected thymocytes rather than genuine infection in most cases. Thus, surviving colonies are in general not HIV-1 infected. However, this apparent lack of infection does not rule out the possibility that any infected hematopoietic precursor cells may have been killed prior to colony formation. Alternatively, HIV-1 infection of the Thy/Liv implants may alter the hematopoietic microenvironment affecting progenitor cell differentiation.

Effects of different primary HIV-1 isolates on CFA. To determine viral characteristics associated with this inhibitory phenomenon, seven additional primary HIV-1 isolates (three SI and four NSI [Table 1]) derived from hemophiliac patients infected during childhood were tested. The SI strains were more aggressive in both the inhibition of CFA as well as thymocyte depletion than were the NSI strains, correlating with a severalfold-greater replicative ability in thymocytes (Table 1).

FIG. 2. (A) Effects of pediatric viral isolates, PT3MO and PT8MO (see Materials and Methods for derivation and definition), on hematopoiesis in vivo. Titers of the isolates were determined by PCR on normal PBMCs in parallel, and 200 IU of each strain was injected into SCID-hu Thy/Liv implants. Each bar represents data obtained from four animals for each condition. Hematopoietic progenitor cell CFA was determined at 3 and 6 weeks postinfection. (B) The CD4/CD8 profiles of thymocytes from SCID-hu Thy/Liv implants at 6 weeks postinfection. Histograms from mock-infected implants and implants infected with HIV-1 strains NL4-3, PT3MO, and PT8MO are indicated. (C) Virus replication of pediatric isolates in Thy/Liv implants. The chart shows proviral loads in thymocytes (number of HIV copies/100,000 cells) from Thy/Liv implants infected with the pediatric isolates PT3MO and PT8MO and with HIV-1NL4-3. Determination of viral loads was performed by quantitative PCR at 3 and 6 weeks postinfection. Each symbol represents a single biopsy sample.
This is consistent with the pathogenicity profiles of the HIV-1<sub>1R,CSF</sub> and HIV-1<sub>NL4,3</sub> molecular clones (Fig. 1A) and with previous studies of different virus strains on thymocytes (17, 20). Additionally, the inhibition of CFA kinetically preceded thymocyte depletion (Table 1). Since colony-forming progenitor cells are distinct from cells of the lymphoid lineage, this difference in kinetics suggests a fundamental difference in the pathogenic effects of HIV-1 on these two cell types.

To investigate the relationship between effects on progenitor cells in SCID-hu mice and the clinical situation, two additional primary HIV-1 isolates (PT3MO and PT8MO) obtained from a pediatric AIDS patient exhibiting severe hematopoietic abnormalities (see Materials and Methods for clinical details) were assessed for the ability to deplete CFA (Fig. 2A). Interestingly, although the PT8MO isolate caused profound depletion of CFA, in contrast to other isolates aggressive against CFA, thymocyte depletion was not induced even by 6 weeks postinfection (Fig. 2B). This was likely due to a decreased replicative ability in thymocytes, as proviral loads were ~350-fold lower at 3 weeks postinfection than those in implants infected with HIV-1<sub>NL4,3</sub> (Fig. 2C). Thus, with the obvious exception of the PT8MO isolate, ability to deplete CFA correlated with thymocyte depletion caused by increased virus loads (Table 1), suggesting a unique phenotype or selective tropism of the PT8MO isolate toward progenitor cells of the non-T-cell lineages. Our data suggest that the severe hematological abnormalities seen in this patient were directly due to the presence of HIV-1. In addition, these results suggest, as did the kinetic study described above, that HIV-1 can have differential effects on thymocytes and hematopoietic progenitor cells. Future studies are planned to map the region of the viral genome responsible for these effects.

**Effects of HIV-1 infection on levels of CD34<sup>+</sup> cells.** To help define the mechanism of HIV-1-induced inhibition of CFA, we focused our studies on the susceptibility of early progenitor cells to virus-mediated effects. Since we find that approximately 15% of fetal liver-derived CD34<sup>+</sup> cells form colonies in vitro, we reasoned that if HIV killed these cells, their loss might be detected in vivo. We first determined that Thy/Liv cells depleted of CD3<sup>+</sup> thymocytes by panning (Fig. 3A) and consequently enriched for CD34<sup>+</sup> cells (Fig. 3B) exhibited a 50- to 100-fold enhancement of CFA (activities of 28,476 ± 20,000 and 134 ± 15 colonies per million input Thy/Liv cells, respectively). A pediatric AIDS patient exhibiting severe hematopoietic abnormalities (see Materials and Methods for clinical details) was assessed for the ability to deplete CFA (Fig. 2A). Interestingly, although the PT8MO isolate caused profound depletion of CFA, in contrast to other isolates aggressive against CFA, thymocyte depletion was not induced even by 6 weeks postinfection (Fig. 2B). This was likely due to a decreased replicative ability in thymocytes, as proviral loads were ~350-fold lower at 3 weeks postinfection than those in implants infected with HIV-1<sub>NL4,3</sub> (Fig. 2C). Thus, with the obvious exception of the PT8MO isolate, ability to deplete CFA correlated with thymocyte depletion caused by increased virus loads (Table 1), suggesting a unique phenotype or selective tropism of the PT8MO isolate toward progenitor cells of the non-T-cell lineages. Our data suggest that the severe hematological abnormalities seen in this patient were directly due to the presence of HIV-1. In addition, these results suggest, as did the kinetic study described above, that HIV-1 can have differential effects on thymocytes and hematopoietic progenitor cells. Future studies are planned to map the region of the viral genome responsible for these effects.

**TABLE 2. Effects of HIV-1 NL4-3 infection on CD34<sup>+</sup> cell levels of Thy/Liv implants.**

<table>
<thead>
<tr>
<th>Group</th>
<th>% Total CD4&lt;sup&gt;+&lt;/sup&gt; cells</th>
<th>CD34&lt;sup&gt;+&lt;/sup&gt; CXCR4&lt;sup&gt;+&lt;/sup&gt; CD45&lt;sup&gt;+&lt;/sup&gt;</th>
<th>Myeloid colonies</th>
<th>Erythroid colonies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mock</td>
<td>98 ± 3</td>
<td>23,000 ± 8,000</td>
<td>120 ± 12</td>
<td>134 ± 15</td>
</tr>
<tr>
<td>Infected</td>
<td>93 ± 3</td>
<td>34,000 ± 22,000</td>
<td>9 ± 2</td>
<td>6 ± 9</td>
</tr>
</tbody>
</table>

a Total cells from the implants were depleted of CD3<sup>+</sup> thymocytes by panning at 3 weeks postinfection. To determine CD34<sup>+</sup> cell levels, the panned cells were stained with anti-CD34, anti-CD45, and anti-CXCR4 monoclonal antibodies. The CD34<sup>+</sup> cell levels were analyzed by setting gates on CD45<sup>+</sup> cells and determining the percentages of cells which were also positive for CD34 as well as for CXCR4. Cells derived from implants from six mock-infected and six virus-infected animals were analyzed. % total CD4<sup>+</sup> cells includes both CD4<sup>+</sup> and CD4<sup>-</sup> CD8<sup>-</sup> thymocytes as assessed by flow cytometry. To determine the number of CD34<sup>+</sup> CXCR4<sup>+</sup> human cells, the number of events detected in 50,000 panned cells was corrected for cell loss during the panning procedure and calculated for total recovery per 1 million input Thy/Liv cells.
Percent recovery of CFA of hematopoietic progenitor cells from HIV-1NL4-3-formed in duplicate. (B) Effect of combination drug treatment postinfection. daily for 3 weeks. Each group consisted of four animals, and assays were per-
treated with drugs daily for 3 weeks; NLDP0-3W, HIV-1NL4-3-infected mice
administered 2 days prior to infection. Recovery of myeloid and erythroid CFA
three-drug combination consisting of AZT, ddI, and protease inhibitor was
CFA present immediately prior to initiation of therapy.

Each time point (not shown). The 3-week time point indicates relative percent of
animals not receiving drug therapy showed values of less than 10% of mock at
 recovery of hematopoietic colonies in drug-treated virus-infected implants rela-
to mock-infected implants following drug treatment is shown. The combination therapy was administered to infected
animals beginning 3 weeks postinfection (when only approximately 10% of the
original hematopoietic colonies could be recovered from infected implants), and
therapy was continued daily. The median values obtained from each mock- and
virus-infected implant at each time point were used to calculate the total percent
recovery of hematopoietic colonies in drug-treated virus-infected implants rela-
tive to mock-infected implants. Each group consisted of four animals. Infected
animals not receiving drug therapy showed values of less than 10% of mock at
each time point (not shown). The 3-week time point indicates relative percent of
CFA present immediately prior to initiation of therapy.

3,086, 8 ± 2, and 342 ± 38 colonies/5 x 10⁶ cells for CD3-depleted, CD3-enriched, and total Thy/Liv cells, respectively). Flow cytometry was then used to evaluate the effect of infection of Thy/Liv implants on CD34⁺ cells (Fig. 3B; Table 2). Total Thy/Liv cells derived from control and infected implants biopsied at 3 weeks postinfection prior to CD4⁺ cell loss but after inhibition of CFA were enriched for CD34⁺ cells by depletion of CD3⁺ thymocytes (Fig. 3A). Since it was difficult to detect CD4 on CD34⁺ cells, we colabeled the CD3-depleted cells with an anti-CXCR4 antibody (12) that binds to the HIV coreceptor (4, 13), along with common leukocyte antigen-specific anti-CD45 to ensure the human origin of all evaluated cells. HIV-1 infection did not deplete the levels of total CD34⁺ cells or those of CD34⁺ CXCR4⁺ cells, although the CFA was decreased to minimal levels (Fig. 3B; Table 2). This finding suggests either that the HIV-1-induced inhibitory effects occur late in the hematopoietic differentiation process or that CD34⁺ cell function (e.g., proliferation and maturation) is impaired by HIV-1 without altering CD34⁺ cell population size. Differentiation pathways via intermediate progenitor cells may be suppressed by the effect of infection on supportive elements, thereby preventing differentiation into their terminal entities. Alternatively, HIV-1-induced CFA inhibition may be the result of direct killing of precursor cells not detected in our assay. However, our data suggest that pluripotent stem cells are not killed, as this would likely result in a decrease of total CD34⁺ cells, which are progeny of pluripotent stem cells. Additional evidence for the survival of pluripotent stem cells during HIV-1 infection is presented below.

Effect of antiretroviral therapy on hematopoietic inhibition. We previously established that we could inhibit HIV replication pharmacologically, using a three-drug combination of AZT, ddI, and a protease inhibitor (A77003) (33). To determine if halting ongoing virus replication would affect HIV-1-induced depletion of CFA, SCID-hu animals were treated for 2 successive days prior to HIV-1 infection, with therapy continued daily. This treatment resulted in an inability to detect proviral DNA sequences in three of four SCID-hu animals at 3 weeks postinfection, and prevented CD4⁺ thymocyte depletion in all four animals. Proviral DNA in the single animal that was positive 3 weeks postinfection (0.3% cells infected) was undetectable at 6 weeks postinfection (33), indicating that this drug combination can clear low-level infection. This treatment also prevented depletion of CFA in these implants (Fig. 4A). Thus, this drug combination was effective at preventing the pathogenic consequences of HIV infection in this in vivo system.

In a subsequent experiment, this combination therapy was administered to animals after colony inhibition (3 weeks postinfection) when virus loads were highest (Table 1; references 3 and 18). Animals not administered drugs exhibited continued decline of CFA (not shown). In contrast, we observed a resurgence of as much as 35% of myeloid and 70% of erythroid colonies in mice that received drugs following the initial loss of CFA (Fig. 4B). However, the rescue of hematopoietic colonies was transient, in that CFA diminished somewhat 6 weeks after therapy. While we were unable to detect a decrease in proviral load in implants of treated animals, we have seen elsewhere that drug treatment generally lowers plasma viremia within 1 week of administration (33). However, viremia is detectable in approximately 40% of infected animals 6 weeks following therapy, suggesting virus breakthrough leading to renewed depletion of CFA. We have noted in our other studies involving the response of T-lineage cells to combination therapies that inclusion of certain other protease inhibitors in the regimen may provide greater therapeutic benefit (33). Thus, it is highly likely that further optimization of the therapeutic regimen used might allow a more prolonged resurgence of CFA. Together, our results establish that the effect of HIV-1 on hematopoietic colony formation is reversible. This
HIV-1 INHIBITS HEMATOPOIESIS IN VIVO 5127


